

# Salts of S-(+)-ibuprofen formed via its reaction with the antifibrinolytic agents aminocaproic acid and tranexamic acid: synthesis and characterization

Hannah M. Frösler, Humbelani S. Ramulumo, Cesarina Edmonds-Smith and Mino R. Caira

## SUPPLEMENTARY MATERIAL

### CONTENTS:

Figure S1: HPLC calibration curve.

Table S1: HPLC gradient elution program.

Figure S2: PXRD patterns of the starting components S-IBU and TXA, and those of the products obtained by liquid-assisted grinding.

Figure S3:  $^1\text{H}$ -NMR spectrum of (S-IBU) $\cdot$ (ACA) $^+$

Table S2: Analysis of the  $^1\text{H}$ -NMR spectrum of (S-IBU) $\cdot$ (ACA) $^+$

Figure S4: Experimental and calculated PXRD patterns for (S-IBU) $\cdot$ (TXA) $^+$ .

Figure S5: FTIR spectra of S-(+)-ibuprofen, TXA and their product.

Figure S6: DSC and TGA curves for (S-IBU) $\cdot$ (ACA) $^+$

Figure S7: DSC and TGA curves for S-IBU) $\cdot$ (TXA) $^+$

Table S3: Solubility data for four solid forms of S-(+)-ibuprofen




Figure S1: HPLC calibration curve.

Table S1: HPLC gradient elution program

| Time (min) | Buffer (% v/v) | Methanol (% v/v) |
|------------|----------------|------------------|
| 0.0        | 80             | 20               |
| 2.0        | 80             | 20               |
| 9.0        | 5              | 95               |
| 12         | 5              | 95               |
| 14         | 80             | 20               |
| 15         | 80             | 20               |




Figure S2: PXRD patterns of the starting components S-IBU and TXA, and those of the products obtained by liquid-assisted grinding.




Figure S3:  $^1\text{H}$ -NMR spectrum of  $(\text{S-IBU})\cdot(\text{ACA})^+$

Table S2: Analysis of the  $^1\text{H}$ -NMR spectrum of  $(\text{S-IBU})\cdot(\text{ACA})^+$

*Experimental details:*

Bruker Ultrashield 300 (300 MHz) and interpreted on MestReNova [1].

1. Chemistry Software Solutions, Mestrelab Research, S.L. MestReNova, Version: 6.0.2-5475. (Copyright, 2009).

| Assignment                    | $\delta$ (ppm) | Integration | Multiplicity | Proton representation (per molecule) | Stoichiometric ratio | Stoichiometric ratio (nearest integer) |
|-------------------------------|----------------|-------------|--------------|--------------------------------------|----------------------|--|
| 4 x CH aromatic (IBU)         | 7.19-7.08      | 3.14        | Doublets     | 4H                                   | 0.79                 | 1                                      |
| CH (2) (IBU)                  | 3.64-3.56      | 0.67        | Quartet      | 1H                                   | 0.67                 | 1                                      |
| CH <sub>2</sub> (7) (IBU)     | 2.42-2.40      | 1.57        | Doublet      | 2H                                   | 0.79                 | 1                                      |
| CH (8) (IBU)                  | 1.87-1.74      | 1.00*       | Multiplet    | 1H                                   | 1                    | 1                                      |
| CH <sub>2</sub> (2) (6AA)     | 1.51-1.46      | 0.46        | Multiplet    | 2H                                   | 0.23                 | -                                      |
| CH <sub>2</sub> (4) (6AA)     | 1.34-1.31      | 2.45        | Doublet      | 2H                                   | 1.23                 | 1                                      |
| 2 x CH <sub>3</sub> (9) (IBU) | 0.86-0.84      | 4.56        | Doublet      | 6H                                   | 0.76                 | 1                                      |




Figure S4: Experimental and calculated PXRD patterns for (S-IBU)·(TXA)<sup>+</sup>.




Figure S5: FTIR spectra of S-(+)-ibuprofen, TXA and their product.




Figure S6: DSC and TGA curves for (S-IBU)·(ACA)<sup>+</sup>




Figure S7: DSC and TGA curves for S-IBU)-(TXA)<sup>+</sup>

Table S3: Solubility data for four solid forms of S-(+)-ibuprofen

| <b>pH 6.5</b>                           | <b>Molarity</b> | <b>Solubility<br/>mg/mL</b> | <b>Relative<br/>solubility</b> |
|---|-----------------|-----------------------------|--------------------------------|
| S-(+)-ibuprofen                         | 0.016           | 3.4                         | 1.00                           |
| (S-IBU) <sup>-</sup> (ACA) <sup>+</sup> | 0.016           | 3.4                         | 1.00                           |
| (S-IBU) <sup>-</sup> (TXA) <sup>+</sup> | 0.018           | 3.7                         | 1.09                           |
| S-(+)-ibuprofen-benzamide               | 0.018           | 3.7                         | 1.09                           |
| <b>pH 2.0</b>                           |                 |                             |                                |
| S-(+)-ibuprofen                         | 0.001           | 0.21                        | 1.00                           |
| (S-IBU)-(ACA)+                          | 0.001           | 0.21                        | 1.00                           |
| (S-IBU)-(TXA)+                          | 0.001           | 0.21                        | 1.00                           |
| S-(+)-ibuprofen-benzamide               | 0.001           | 0.21                        | 1.00                           |
|   |                 |                             |                                |